Lilly Stock Down 5% This Month: Should You Buy the Dip?

Eli Lilly (LLY) stock declined 5.1% this month, despite robust Q2 earnings and sales beats fueled by strong Mounjaro and Zepbound performance. The primary driver for the dip was investor disappointment over phase III data for its oral GLP-1 candidate, orforglipron, which achieved 12.4% weight loss, falling short of market expectations for rival injectable outcomes. Despite this setback and increasing competition in the obesity market, LLY's raised 2025 financial outlook, projecting over 30% revenue growth, and its diversified pipeline indicate continued strong underlying business fundamentals, prompting debate on whether the market reaction was overblown.

Analysis

Eli Lilly's stock has demonstrated a notable disconnect from its strong operational performance, declining 5.1% this month despite a second-quarter earnings and sales beat and a raised full-year financial outlook. The primary catalyst for the negative sentiment was the Phase III trial data for its oral obesity drug, orforglipron, which, while meeting its primary endpoint, delivered a 12.4% weight loss that fell short of the high expectations set by injectable competitors like Novo Nordisk's Wegovy. A high patient discontinuation rate of 24.4% in the study further tempered investor enthusiasm. Nonetheless, the company's fundamental growth drivers remain robust, with Mounjaro and Zepbound now accounting for approximately 50% of total revenues and production capacity rapidly expanding, with plans to produce at least 1.8 times more incretin doses in the second half of 2025 compared to the prior year. However, significant headwinds persist, including intense competition from Novo Nordisk, Amgen, and Viking Therapeutics in the projected $100 billion obesity market, U.S. net price declines, and the recent exclusion of Zepbound from CVS Caremark's preferred drug list, which is expected to dampen Q3 volume growth. While the stock's forward P/E of 25.06 is elevated compared to the industry, it remains below its five-year average, and upward revisions to 2025 and 2026 earnings estimates suggest underlying confidence in its diversified pipeline and projected 30%-plus revenue growth for 2025.

Key Decisions for Investors

• Consider the recent stock price weakness as a potential entry point, as the market's disappointment over orforglipron's trial data may overshadow strong underlying fundamentals, including a raised financial outlook and robust growth from its core GLP-1 franchise.
• Investors should closely monitor the competitive landscape, particularly the progress of Novo Nordisk's oral Wegovy and pipeline candidates from Amgen and Viking, as well as the near-term impact of Zepbound's exclusion from the CVS Caremark formulary on Q3 sales volumes.
• Evaluate Lilly's execution on its aggressive production ramp-up for Mounjaro and Zepbound, as meeting demand is critical to sustaining its projected 30% revenue growth and justifying its premium valuation.
• Look beyond the current GLP-1 focus and assess progress in the broader pipeline, including the next-generation obesity drug retatrutide and recent M&A in oncology and gene therapy, as these are key to long-term diversification and growth.